@article{oai:u-ryukyu.repo.nii.ac.jp:02016198,
 author = {Suzui, Masumi},
 issue = {1-2},
 journal = {琉球医学会誌 = Ryukyu Medical Journal},
 note = {Acyclic retinoid (ACR), a novel synthetic retinoid, can prevent the recurrence of hepatomas after surgical resection of primary tumors, but the molecular mechanisms by which ACR exerts anti-tumor effects are not known. In recent studies we found that growth inhibition of human hepatoma cells by ACR is associated with induction of p21^<CIP1> and inhibition of expression of cyclin D1. $ \beta $-Catenin stimulates cyclin D1 promoter activity through T cell factor (TCF) in the HepG2 human hepatoma cell line, and this activity is inhibited by ACR. We also found that ACR activates retinoic acid receptor $ \beta $ and induces transcriptional activation of p21^<CIP1> in human hepatoma and squamous cell carcinoma cells. These novel effects of ACR suggest that this agent might be useful in the chemoprevention and therapy of various malignancies. These studies and their implications are summarized and discussed in this article., 論文},
 pages = {1--9},
 title = {[総説］Effects of acyclic retinoid on cell cycle progression and signal transduction},
 volume = {23}
}